Empagliflozin
Empagliflozin
Empagliflozin (pronounced em-pa-gli-flo-zin) is a medication used to treat Type 2 diabetes. It is classified under the drug class known as Sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Etymology
The name "Empagliflozin" is derived from its chemical structure. The "empa" part of the name is an abbreviation of "empirical", referring to the empirical formula of the compound. The "gli" part of the name is derived from "glucose", as the drug works by inhibiting glucose reabsorption in the kidneys. The "flozin" suffix is common among other SGLT2 inhibitors.
Usage
Empagliflozin is used in the management of Type 2 diabetes to improve glycemic control in adults. It works by blocking the reabsorption of glucose by the kidneys, increasing glucose excretion, and lowering blood glucose levels.
Related Terms
Side Effects
Common side effects of Empagliflozin include urinary tract infections, increased urination, and yeast infections. Serious side effects may include ketoacidosis, kidney problems, and low blood sugar.
Interactions
Empagliflozin may interact with other medications, including diuretics, insulin, and rifampin. It is important to inform healthcare providers of all medications being taken while on Empagliflozin.
Precautions
Before taking Empagliflozin, individuals should inform their healthcare provider if they have a history of kidney problems, liver disease, or if they are on a low salt diet.
External links
- Medical encyclopedia article on Empagliflozin
- Wikipedia's article - Empagliflozin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski